Constipation is a major health problem worldwide that requires effective and safe treatment options. Increasing evidence indicates that disturbances in gut microbiota may be a risk factor for constipation. Administration of lacidophilin tablets shows promising therapeutic potential in the treatment of inflammatory bowel disease owing to their immunomodulatory properties and regulation of the gut microbiota. The focus of this study was on investigating the ability of lacidophilin tablets to relieve constipation by modulating the gut microbiome. Rats with loperamide hydrochloride induced constipation were treated with lacidophilin tablets via intragastric administration for ten days. The laxative effect of lacidophilin tablets was then evaluated by investigating the regulation of intestinal microflora and the possible underlying molecular mechanism. Our results reveal that treatment with lacidophilin tablets increased the intestinal advancement rate, fecal moisture content, and colonic AQP3 protein expression. It also improved colonic microflora structure in the colonic contents of model rats mainly by increasing Akkermansia muciniphila and decreasing Clostridium_sensu_stricto_1. Transcriptome analysis indicated that treatment with lacidophilin tablets maintains the immune response in the intestine and promotes recovery of the intestinal mechanical barrier in the constipation model. Our study shows that lacidophilin tablets improve constipation, possibly by promoting Akkermansia colonization and by modulating the intestinal immune response.
Alpinia officinarum Hance has a medicinal history of thousands of years in treating cough, diabetes, and gastrointestinal system diseases, and it is also a medicine food homology (MFH) plant in China. To evaluate the pharmacological activities of polysaccharides from the rhizomes of A. officinarum, polysaccharides were initially obtained by hot-water extraction and the ethanol precipitation method. A homogenous polysaccharide designated as AOP-w was isolated by a DE-52 column. The proposed structure was elucidated and the immunoregulatory effects on RAW 264.7 macrophage cells were evaluated. The results showed that AOP-w had a molecular weight of 5.26 kDa, and mainly consisted of galactose and glucose (molar ratio of 0.12:0.88). Its backbone comprised α-(1→4)-Glcp, α-(1→4,6)-Glcp and β-(1→3,4)-Galp residues, terminated by α-(1→6)-Glcp and T-Glcp residues. AOP-w was nontoxic to RAW 264.7 cells, but demonstrated promotion in cell proliferation within a 100 μg/mL concentration. The immunostimulatory effects of AOP-w were confirmed by the elevated NO production of AOP-w-treated cells. Moreover, the RNAseq was conducted and the results showed that AOP-w may activate the TNF and NF-κB signaling pathways by binding to Toll-like receptors, thereby affecting the immune modulatory activity of RAW264.7 cells. These results suggest a high potential of AOP-w from A. officinarum for immunotherapeutic applications.
Bifidobacterium longum plays a critical role in the human gut and exhibits diverse probiotic functions. Achieving high‐density fermentation of B. longum largely depends on the composition of the culture medium and fermentation conditions. This study aimed to optimize the medium composition and fermentation parameters for B. longum HSBL001, using viable cell counts and optical density at 600 nm (OD600) as indicators. The goal was to improve biomass yield and support the development and industrial application of highly active probiotic preparations. The optimal medium composition and culture conditions were established using a combination of single‐factor experiments, the Plackett–Burman design, the steepest ascent method, and the central composite design. The optimized culture medium consisted of yeast extract (19.524 g/L), yeast peptone (25.85 g/L), arginine (0.599 g/L), glucose (27.36 g/L), MnSO 4 (0.09 g/L), MgSO 4 (0.8 g/L), Tween‐80 (1 g/L), l ‐cysteine hydrochloride (0.24 g/L), and methionine (0.15 g/L). The optimal culture conditions included an initial pH of 7.0, 5% inoculum size, and incubation at 37°C, yielding a final viable cell count of 4.20 × 10 9 colony‐forming units (CFU/mL). In a 3 L bioreactor, the viable cell count reached 1.17 × 10 10 CFU/mL, which was 1.786 times higher than that achieved with the modified MRS medium. These findings demonstrate that the optimized medium and fermentation conditions are well‐suited for high‐density cultivation of B. longum HSBL001 and provide a basis for its industrial application.
The Shenlingcao oral liquid (SLC), derived from traditional clinical formulations, can enhance physical strength and vitality during chemotherapy for malignant tumors. Previous studies have indicated that SLC can enhance the quality of life and daily functioning of patients with non-small cell lung cancer (NSCLC) within 6 months after adjuvant chemotherapy following radical surgery. Nevertheless, its precise mechanism of action is unclear. To elucidate the function and underlying mechanism of SLC in enhancing the effect of cisplatin in treating NSCLC. UPLC-Q-Exactive Plus-MS/MS was used to characterize the chemical constituents of SLC. The main gene targets and the pathways of SLC that impact NSCLC were predicted using network pharmacology. A mouse model of Lewis lung cancer and the combination of transcriptomics, metabolomics, and 16S rRNA analysis were used to investigate the underlying mechanisms of the SLC-cisplatin combination in influencing the pathology of NSCLC. The SLC-cisplatin combination significantly reduced tumor volume and weight (P<0.01), boosted T lymphocytes (P<0.05), increased cleaved-caspase-3/caspase-3 expression (P<0.05), and decreased p-PI3K/PI3K, p-AKT/AKT, and Bcl-2/Bax protein levels (P<0.05) compared with cisplatin monotherapy. It also improved the gut flora by enriching the abundance of Bacteroidaceae, S24-7, and Porphyromonadaceae, while modulating metabolic pathways, including caffeine metabolism and fatty acid degradation. SLC enhanced the effect of cisplatin in inhibiting NSCLC by inducing cell apoptosis, augmenting immune responses, balancing the gut microbiota, and regulating key metabolic pathways. Our findings highlight the potential of SLC as an effective adjuvant therapy for NSCLC.
Background/Objectives: Cancer-related fatigue (CRF) is one of the most prevalent and disabling symptoms among patients with cancer, but its underlying mechanisms and effective management strategies have not yet been fully elucidated. Increasing evidence suggests that the microbiota–gut–brain axis (MGBA) may contribute to the pathogenesis of CRF by integrating nutritional status, intestinal barrier integrity, microbial metabolites, immune responses, and host energy metabolism. However, direct causal evidence in human CRF remains limited, and several mechanistic insights are extrapolated from other disease models. This narrative review aims to synthesize evidence for nutritional MGBA–CRF regulatory mechanisms, focusing on microbiota-associated biomarkers and microbiome-targeted dietary interventions, and to distinguish directly observed in a CRF population from indirect hypothetical mechanisms. Methods: This review synthesizes current evidence on the nutritional regulatory mechanisms linking the MGBA to CRF, with particular attention to microbiota-associated biomarkers and dietary or microbiome-targeted interventions. Results: Microbiota dysbiosis, reduced production of short-chain fatty acids, disrupted tryptophan metabolism, and increased intestinal permeability may lead to systemic inflammation, neuroendocrine dysfunction, and impaired mitochondrial function, thereby exacerbating fatigue. Moreover, nutritional factors, dietary patterns, and microbiota-targeted interventions may help restore microbiota homeostasis and alleviate fatigue-related biological dysregulation. Conclusions: A deeper understanding of MGBA may help in developing personalized nutritional strategies for patients with cancer experiencing fatigue symptoms and support more effective management of CRF.